Page 348 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
measured by
planimetric
calculation
during TRUS.
After a PCA
diagnosis, men
are referred to
the regular
medical circuit
(which may be
the ERSPC
centre), where
decisions on
treatment are
made. 151
Four tertiary care Patients who Office visits, review of general health and urinary symptoms, Criteria for recommending NR
academic medical would otherwise DRE and PSA every 6 to 12 mo, rebiopsies within 18 mo of treatment were
m
canters, US 109 be considered starting AS and subsequently every 1 to 3 yr or prompted by a nonstandardized and
[19233410] for surgery or change in clinical status (e.g., significant and sustained PSA physician specific.
radiation due to increase). MRI of the prostate was selectively used at
1991-2007 a life diagnosis and every 1 to 3 yr after starting AS.
expectancy >10
yr, and were
defined as age
≤75 yr, clinical
stage T1-T2a,
PSA ≤10
ng/mL, ≤3
positive cores
at diagnostic
biopsy, Gleason
score ≤6, no
active treatment
for a minimum
of 6 mo after
the second
biopsy.

C-92